Stephen Tulipano, Javelin's Chief Financial Officer, stated, "2007 was a landmark year for Javelin culminating in our first commercial approval of Dyloject. The Company has continued to efficiently move each of its three important acute pain products through clinical development. Simultaneously, we have established a dedicated sales force in the United Kingdom. In 2008, we look forward to building on the success of 2007 and capitalizing on the opportunities before us.”

Financial Performance for the Year Ended December 31, 2007:

For the year ended December 31, 2007, Javelin recorded no revenue, compared to $842,000 in grant revenue from the U.S. Department of Defense in 2006. Javelin incurred approximately $32.9 million in operating expenses for the year ended December 31, 2007 compared to operating expenses of $20.5 million for the year ended December 31, 2006.

Research and development expenses for the year ended December 31, 2007 were $19.0 million, compared to $10.9 million for the same period in 2006. Total research and development expense increased by $8.1 million in 2007 compared to 2006 due primarily to increased clinical trial costs, manufacturing costs, and expenses associated with increases in the number of full-time employees, including stock based compensation expense.

Selling, general and administrative expenses for the 12 months ended December 31, 2007 were $13.8 million compared to $9.6 million for the same period in 2006. The $4.2 million increase was mainly due to salaries and other expenses associated with increased headcount, including stock based compensation expense, as well as increased sales and marketing expenses related to our, pre and post launch activities for Dyloject in the U.K., including our U.K. sales force.

Financial Performance for the Fourth Quarter Ended December 31, 2007:

For the three months ended December 31, 2007, Javelin recorded no revenue, compared to approximately $114,000 of grant revenue from the U.S. Department of Defense in the same period of 2006. Javelin incurred approximately $10.2 million in operating expenses for the three months ended December 31, 2007, compared to $6.0 million for the same period in 2006.

Research and development expenses for the three months ended December 31, 2007 were $5.7 million, compared to $2.8 million for the same period in 2006. Total research and development expense increased $2.9 million during the quarter compared to the same period a year ago due primarily to increased clinical trial expenses, headcount, and costs associated with the advancement of each of the three product candidates.

Selling, general and administrative expenses were $4.5 million for the three months ended December 31, 2007 compared to $3.1 million for the same period in 2006. The increase resulted primarily from additional headcount and costs associated with expanding and improving administrative infrastructure, and from increased promotional and marketing costs associated with the pre and post launch activities for Dyloject in the U.K., including our U.K. sales force.

About Javelin

With global headquarters located in Cambridge, MA, and European offices in Cambridge, UK, and Cologne, Germany, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at www.javelinpharmaceuticals.com.

Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.